论文部分内容阅读
目的:观察核苷类抗病毒药物恩替卡韦对首次接受抗病毒药物治疗的乙型肝炎以及由乙型肝炎引起感染的相关肝病的治疗作用。方法:选择2011年11月到2013年11月来我院就诊的200例乙型肝炎患者,上述患者在没有接受过核苷类药物或者是干扰素抗病毒药物的治疗前,使用恩替卡韦对患者进行抗病毒治疗,观察治疗后HBVDNA、肝功能、乙型肝炎病毒血清标志物的变化情况。结果:在接受治疗的第2周、4周、12周、24周、48周、96周,患者体内转氨酶的复常率分别是9.5%、27.5%、65.5%、77.5%、93.5%、98.5%。疗程结束时,HBVDNA降到了检测线以下的比率分别是:13.0%、74.5%、88.0%、94.0%、99.0%、99.0%。同时,HBeAg的阴转率和血清学转换率分别是:25.71%和22.86%。结论:恩替卡韦在治疗乙型肝炎时有显著的疗效,值得广大医学工作者在治疗乙型肝炎病毒时广泛推广使用。
OBJECTIVE: To observe the therapeutic effect of entecavir, a nucleoside antiviral drug, on hepatitis B patients receiving first antiviral therapy and the related liver diseases caused by hepatitis B infection. METHODS: A total of 200 hepatitis B patients treated in our hospital from November 2011 to November 2013 were enrolled in this study. Patients were enrolled before treatment with nucleoside or interferon antiviral drugs Antiviral therapy, HBVDNA after treatment, liver function, hepatitis B virus serum markers changes. Results: The normal rates of aminotransferase in the patients were 9.5%, 27.5%, 65.5%, 77.5%, 93.5% and 98.5 respectively at the 2nd week, 4th week, 12th week, 24th week, 48th week and 96th week after treatment %. At the end of the course of treatment, the rates at which HBVDNA dropped below the test line were: 13.0%, 74.5%, 88.0%, 94.0%, 99.0%, 99.0%, respectively. Meanwhile, the rates of negative conversion and seroconversion of HBeAg were 25.71% and 22.86%, respectively. Conclusion: Entecavir has a significant effect in the treatment of hepatitis B, which is worth widely used by medical workers in the treatment of hepatitis B virus.